HKeyBio Launches HKEY-ExE™ 1.0 Preclinical Framework to Accelerate Drug Development for Eosinophilic Gastrointestinal Disorders
核心洞察
HKeyBio (搜索) announced the launch of HKEY-ExE™ 1.0, an integrated preclinical evaluation framework for eosinophilic esophagitis (搜索) (EoE), eosinophilic gastroenteritis (搜索) (EgE), and related EGIDs.
The framework integrates disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research support for drug developers.
HKEY-ExE™ 1.0 targets candidates addressing IL-4 (搜索)/IL-13 (搜索), IL-5 (搜索), TSLP (搜索), Siglec-8 (搜索), and the CCR3 (搜索)/eotaxin axis, aiming to clarify in vivo activity and biomarker modulation.
BOSTON and SUZHOU, China — HKeyBio (搜索), a preclinical contract research organization specializing in autoimmune and allergic diseases, today announced the launch of HKEY-ExE™ 1.0, a comprehensive preclinical evaluation framework designed to address long-standing bottlenecks in drug development for eosinophilic esophagitis (搜索) (EoE), eosinophilic gastroenteritis (搜索) (EgE), and related eosinophilic gastrointestinal disorders (搜索) (EGIDs).
The new framework arrives at a time when EoE drug development is advancing, yet broader EGIDs continue to present significant challenges in model construction, histological evaluation, biomarker selection, and translational data interpretation. HKEY-ExE™ 1.0 aims to provide drug developers with a more systematic and interpretable preclinical research platform.
A Framework Built on Four Core Modules
HKEY-ExE™ 1.0 is structured around four integrated modules that span the full preclinical evaluation workflow. The first module, disease modeling for EoE and related EGIDs, leverages allergen-induced modeling strategies and the company's immuno-inflammatory disease research experience. Protocols can be adapted by candidate mechanism, molecule type, target biology, development stage, and project objectives. For EoE studies, evaluation may focus on eosinophil infiltration, inflammatory cell recruitment, tissue injury, epithelial barrier changes, and fibrosis-related alterations. For EgE and other EGIDs, the framework can be extended to additional gastrointestinal tissue sites and disease-related molecular signals.
The second module addresses multidimensional efficacy endpoint evaluation. HKeyBio (搜索) emphasizes that efficacy assessment in eosinophilic gastrointestinal diseases cannot rely on a single endpoint. The framework combines histology, cytology, molecular biology, pathology, and biomarker analysis. Depending on study objectives, endpoints may include histopathological assessment of esophageal and gastrointestinal tissues, quantitative analysis of eosinophil and inflammatory cell infiltration, detection of inflammatory cytokines and chemokines, evaluation of markers related to tissue injury, mucosal inflammation, and fibrosis, and assessment of candidate drug effects on inflammatory responses, tissue remodeling, and disease progression-related processes.
Type 2 Biomarker Analysis and Translational Support
The third module focuses on type 2 and eosinophilic inflammation biomarker analysis. HKeyBio (搜索) has established biomarker detection and analysis capabilities for key inflammatory pathways, including IL-4 (搜索), IL-5 (搜索), IL-13 (搜索), TSLP (搜索), eotaxin family chemokines, and other molecules related to eosinophil recruitment, activation, and tissue infiltration. These studies are designed to help research teams evaluate expected pathway activity, inflammatory cascade modulation, and the scientific rationale for later-stage development.
The fourth module provides cross-indication translational research support. EoE, EgE, and other allergic inflammatory diseases share overlapping features, including type 2 inflammation, eosinophil recruitment, barrier dysfunction, and tissue remodeling. HKEY-ExE™ 1.0 supports mechanism validation, model selection, endpoint design, and translational pathway assessment for multi-indication strategies.
Addressing Unmet Preclinical Needs
EoE is a chronic, antigen-driven, immune-mediated disease of the esophagus, characterized by eosinophil infiltration, inflammation, epithelial barrier dysfunction, tissue injury, and remodeling. EgE and other non-esophageal EGIDs may involve the stomach, small intestine, colon, or multiple gastrointestinal tissue sites, creating complexity that has historically hampered preclinical research.
For drug candidates targeting IL-4 (搜索)/IL-13 (搜索), IL-5 (搜索), TSLP (搜索), Siglec-8 (搜索), the CCR3 (搜索)/eotaxin axis, and other eosinophilic inflammation-related pathways, early preclinical studies need to clarify in vivo activity, tissue inflammation reduction, biomarker modulation, and cross-indication potential — precisely the capabilities HKEY-ExE™ 1.0 is designed to deliver.
"EoE, EgE, and related EGIDs share important immuno-inflammatory characteristics, but they differ in affected tissue sites, pathological features, and endpoint evaluation requirements," said a representative of HKeyBio (搜索). "HKEY-ExE™ 1.0 is designed to provide global drug developers with more systematic, interpretable, and mechanism-oriented preclinical research support."
HKeyBio (搜索)'s core technical team brings more than 20 years of autoimmune disease drug development experience and has supported more than 500 autoimmune disease-related IND research programs. The company maintains both rodent and non-human primate preclinical platforms covering disease modeling, efficacy evaluation, mechanism-of-action studies, biomarker analysis, pathology testing, and translational medicine research. Looking ahead, HKeyBio indicated it will continue to strengthen disease model resources and translational research capabilities for EoE, EgE, and related EGIDs.